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Abstract 
The research question initially formulated for this study was to attempt to set a numerical 
target for the total yearly cost of MS to the Norwegian society, and relate the cost and 
patients´ experienced quality of life to illness severity. As work progressed, the question 
of how much confidence may be put in this kind of information in Norway as for today 
turned into another main issue. It turned out that much of the information that could be 
used for our study was so imprecise or unreliable that giving an impression that the 
information could be used to give an acceptably precise single estimate of the cost of MS 
to the Norwegian society would be seriously misleading. Therefore both “conservative” 
and “best” estimates are given. A conservative estimate of the yearly cost of MS to the 
Norwegian society around year 2002 is NOK 1 836 million. A best estimate is  
NOK 4 033 million, more than twice the conservative estimate. Mainly three factors 
account for the difference between the estimates: Uncertainty on what elements should be 
included in cost-of-illness studies, uncertainty on how some cost elements should be 
valued, and a combination of differences in information on the same phenomena in 
different sources of information and the researchers´ choices on how to handle them. For 
decision making purposes the combined effect of differences in information from 
different sources and the researchers´ choices on how to handle them is most grave since 
it will usually go unrecognized.  
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When related to illness severity, the total cost per patient to society seem to increase, and 
the patients experienced quality of life to decrease, in a close to linear fashion with 
increasing EDSS-levels 1. However, a warning should be raised that  because of the 
uncertainties as those mentioned, Norway probably has a long way to go before studies 
like ours in general might be regarded as providing acceptable information for decisions 
as important as those that have to be made in the health sector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1 The EDSS, Kurtzke`s “Expanded Disability Status Scale”, is the most common tool used to express 
   illness severity in MS. The scale ranges from 0 (no disability) to 10 ( dead due to MS) and is divided 
   in 20 half-point steps 
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Introduction 
 
Multiple sclerosis (MS) is a chronic, eventually progressive disorder of the central 
nervous system, characterized by demyelination and axonal loss with resultant 
accumulation of neurological impairment and disability. The progressive loss of function 
results in a high level of disability (Grima et al, 2000), and more than 50 % of persons 
with MS are unemployed within 10 years from diagnoses (Bourdette et al, 1993). The 
onset of the illness is normally between 20 and 40 years of age and it is the second most 
common cause of disability in young and middle-aged adults (Hauser, 1994). The illness 
also typically has a long duration, mean 40 years (Weinshenker et al, 1989), and may in 
rare cases also cause death. It has therefore long been acknowledged that MS brings high 
costs upon both patients and society, but also that successful treatment may bring 
comparably large gains. During the 1990s immunomodulatory drugs were introduced. 
These are costly and do not cure the illness, but may delay progression and reduce at least 
some costs. The effects are however modest and uncertain. The Norwegian Multiple 
Sclerosis National Competence Center has initiated work to develop a tool to be used to 
illuminate the combined effect on costs and gains. This article refers the findings from 
the first phase of this work, the setting of a numerical target for the cost of the illness to 
the Norwegian society, and relating the cost and patients experienced quality of life to 
illness severity.  
 
 
Methods, material and terminology 
 
Our study may be classified as a combined top-down/bottom-up cost-of-illness study 
with the human-capital method used to set a numerical target for the cost of sick absence 
from work, early retirement and premature death. We made no special attempt, however, 
to make the study fit perfectly into any given such classification scheme. Information 
from a wide range of sources was gathered and attempted combined in a way that might 
hopefully provide the best possible results.  
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Most of the sources used gave information of relevance for the setting of numerical 
targets for only one single or a limited group of cost elements. These sources will be 
briefly commented upon below in relation to the specific numerical targets attempted set. 
One of the sources, however, a postal survey among MS-patients in Hordaland County, 
provided a broader set of information, both information that could not be gathered from 
other sources, but also information to be used to check the consistency of information 
gathered in different ways, and is therefore given a more general comment below.  
 
Hordaland County was chosen as geographic area for the survey because it is a county for 
which the files at the Multiple Sclerosis National Competence Center are assumed to be 
especially complete, in that they contain all persons in the county with a MS-diagnosis 
according to the Poser criteria (Grytten et al., 2006). These persons can be said to 
comprise the total MS-population, or the population of registered MS-patients in 
Hordaland County. It was considered possibly unethical, however, to send questionnaires 
asking for information about their MS to all these persons because not all of them might 
even be aware of their diagnoses, and some would regard themselves as free of MS even 
if they were aware that they had once got the diagnoses. Neither should it be necessary to 
send questionnaires to these persons, asking questions on the cost to society of their 
illness, since logically there should be none. Therefore, two neurologists at Haukeland 
University Hospital, one of the authors and one other, surveyed the files and removed all 
the persons they considered might not to be aware of or feel any consequences of their 
MS. The remaining persons should then be the part of the total patient population in 
Hordaland County that should be relevant for our study. In the study, this population is 
denoted “the relevant patient population in Hordaland County”. The relevant patient 
population in Hordaland County comprised 526 persons in 2002. The questionnaire sent 
to these patients was structured into 7 different parts, background information, 
ambulatory care, institutionalization, support and assistance, drug use, employment status 
and quality of life 1. To minimize the risk of recall error the questions asked were about 
                                                 
1 Freddie Henriksson, Sten Fredrikson, T. Masterman  and Bengt Jönsson were so kind to provide us with 
   the questionnaire they had used in their study on costs, quality of life and disease severity in Sweden in 
   1998. Our questionnaire was in all important respects made identical to their questionnaire for 
   comparison purposes. We thank  Henriksson, Fredrikson, Masterman and  Jönsson for their generosity 
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the situation at the moment the questionnaire was answered or the last preceding month, 
with only a few exceptions. The exceptions where mainly questions about support in the 
form of adaptations of houses and cars, and helping aids purchased or received, where 
longer perspectives were assumed more suitable. Also, some questions on illness history 
were for longer time periods. 
 
423 of the patients, 81 %, responded and there were no significant differences between 
the groups of responders and non-responders concerning sex, age and kind of MS at 
outburst. Since the notion “the relevant patient population”, however, was coined 
specifically for the gathering of information from Hordaland County for our study, no 
information at the outset existed on the size of the corresponding population nationally. 
This population, being the population that would be relevant for extrapolations of the 
survey findings, and for that reason denoted “the relevant national patient population” in 
the article, therefore had to be estimated. We did this by assuming that the ratio of 
patients in the relevant patient population to the total MS-population was the same in 
Norway as a whole as in Hordaland County. Until some time before we made our study it 
had generally been assumed that the prevalence of MS in Hordaland County might be 
approximately 20 % higher than in the rest of the country (Fuglset, Mehling, 1996). If so, 
that would indicate a size of the total Norwegian MS-population of approximately 6 500 
patients, with 4 670 patients in the relevant patient population. More recently the 
prevalence of MS in Hordaland County and the rest of Norway have been assumed to be 
reasonably identical. In that case the total Norwegian MS-population should be more like 
a 7 740 patients, with approximately 5 570 patients in the relevant patient population.  
 
Since a relatively wide specter of information for our study was gathered through the 
postal survey, two limitations of this information and our further extrapolations of it 
should be born specifically in mind. First, since our exclusion of patients assumed not to 
be aware of or not to feel any consequences of their MS was based on judgment, some 
patients having MS with cost effects to society may have been excluded. To the extent 
this has been the case, our estimates of the cost of MS to the Norwegian society may be 
somewhat too low. Hopefully, however, this possible underestimation should be of 
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modest magnitude since the exclusion of patients was done with great care by qualified 
neurologists. Second, the cost effects to society of the relevant MS-population in 
Hordaland County may not be representative for the corresponding cost effect in other 
parts of Norway, both because patients in Hordaland County may receive different 
treatment etc. than other Norwegian patients, and because the size of the relevant patient 
population in Hordaland County may not be representative of the size of this population 
in other parts of the country. Differences in treatment may for instance be due to 
Hordaland County containing Norway`s second largest city and being served by its own 
university hospital, different employment opportunities for disabled persons in different 
parts of Norway etc.. However, imperfect knowledge of the populations of MS-patients 
in different parts of the Norway made sampling aimed at providing a more representative 
sample difficult. On the other hand, Hordaland County comprises both rural and urban 
areas like most other counties in Norway, and contains approximately 10 % of the MS-
patients in the country. This should contribute to make the MS-population in Hordaland 
County reasonably representative also for the national population what treatment etc. is 
concerned. The possible effect of eventual non-representativeness of our chosen survey 
population in this respect might therefore also, in our opinion, be expected to be modest. 
Similar representativeness problems have also faced researchers in other countries, and 
mostly, also they have chosen to rely on geographically delimitated samples. The 
uncertainty of the size of the relevant national MS-population is graver since it is 
absolute, of considerable magnitude, and will be transferred directly into all results based 
on extrapolations of information gathered from our sample of MS-patients in Hordaland.  
 
Even more important is it, though, that this uncertainty on the size of the relevant national 
MS-population only is one striking example of a more general problem that we typically 
encountered during our work. It turned out that much of the information that could be 
found was so imprecise or unreliable that giving an impression that it could be used to 
give an acceptably precise single estimate of the cost of MS to the Norwegian society 
would be seriously misleading. Therefore, both “conservative” and “best” estimates are 
given for a lot of numbers. Whenever information from different sources varied, we 
chose the information that would contribute to the lowest cost of MS to the Norwegian 
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society as our conservative estimate, given that we considered it to be of reasonably good 
quality. If the information, however, in our opinion could be suspected to be directly 
erroneous, we made adjustments we considered reasonable. The “best” estimates were 
based on the authors´ subjective evaluation of all available information. In line with the 
considerations above, we chose 4 670 persons as the conservative estimate of the size of 
the relevant national MS-population, and 5 570 persons as the best estimate. In addition 
to the term “the relevant patient population”, we also coined two other terms, “ideal or 
close to ideal information” and “volume- and value components”, specifically for the 
purpose of our work. 
  
Ideal or close to ideal information is used to denote information that in principle should 
have been collected and presented to give a true and complete picture of the phenomena 
under study. For example, market prices free of taxes and subsidies should in general be 
expected to give a true and complete picture of the cost to society in terms of units of 
resources consumed, and hospital records a comparable picture of for example the 
number of bed-days in hospitals. We have sought to use this kind of information 
whenever available. 
 
The cost to society of resources used or generation of welfare lost due to for example an 
illness 1 is the product of the number of units of resources used or generation of welfare 
lost, and the cost to society of each unit. Ideally, the best information on unit costs should 
be combined with the best information on the number of units consumed or lost to 
produce the most correct numerical targets for the cost to society. The information may 
however be found in different sources, given for different units of measurement, so 
compromises may have to be struck. For hospital stays for example, information on the 
cost to society of each unit of the specific resources consumed during the stay, like 
nurses´ time, food etc., measured in natural units for each kind of resource, will normally 
be more correct than information on the cost to society of more aggregated unit measures 
                                                 
1 The use of resources should take into account all resources, human as well as physical,  to diagnose, 
   treat or nurse etc., or to give other forms of help or support to patients due to their illness. The reduced 
   generation of welfare should include all reductions in the patients´, and possibly also their families and 
   friends  possibilities or ability to perform activities that would have contributed to increased welfare  
   for themselves or others. 
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as for example “bed-days” etc.. Often however, information on the number of “units” 
consumed or lost is recorded more systematically for more aggregated unit measures. In 
our work we searched for the units of measurement for which we could find or produce 
the most ideal corresponding information on both the number of units consumed or lost, 
and the same units´ cost to society. The number of such measurement units consumed, or 
of generation of welfare lost is denoted the “volume component” of the cost to society of 
this resource usage or loss of welfare generation in the article, and the assumed cost to 
society of each of these units, the “value component”. For hospital stays for example, 
since the information on unit costs to society of the individual resources might be more 
easily aggregated to costs per bed-day than the other way around, we chose bed-days as 
the compromising unit of measurement for the volume- and value components of the cost 
of these stays.  The notation tells that the information used for the setting of the 
numerical target for, for example the costs to society of hospital stays, was chosen not 
solely because of availability, but because it was the information that was considered to 
be the best available for the purpose. The notation, in our opinion, also contributes to 
make the presentation of the findings of our study as simple and precise as possible. 
 
Some information gathered both through the survey and from other sources was given in 
monetary values. In some cases, these values included taxes or subsidies. This has been 
adjusted for so that all the monetary values presented in the study are free of taxes and 
subsidies to make them reflect cost to society.  
 
 
Results 
 
Table 1-3 refers the main findings of our work. 
 
 
 
 
 
 
 8
Table 1 Conservative and best estimates of the total yearly cost of MS to the 
Norwegian society around 1 year 2002 
               
 
 
Conservative estimate Best estimate
DIRECT ECONOMIC COST: 
Drugs 196 400 000 285 759 000
Ambulatory care 105 059 000 156 275 000
Institutionalization 272 535 000 343 942 000
Support and assistance 244 861 000 663 402 000
 
Sum direct economic costs 818 855 000 1 449 378 000
 
INDIRECT ECONOMIC COST: 
Patients´ reduced participation in 
paid work  1 016 876 000 1 910 176 000
 
SOCIOECONOMIC COST: 
Reduced quality of life 0 673 750 000
 
TOTAL 1 835 731 000 4 033 304 000
 
 
Table 2 Average total cost per patient to the Norwegian society for 
                        EDSS-levels 1-9 around 2002 (NOK 1000) 
 
              EDSS 
Cost estimate: 
1 2 3 4 5 6 7 8 9 
Best 382,4 402,5 596,8 687,0 939,1 937,6 884,9 1354,7 1235,3 
Conservative 233,1 234,3 370,8 424,2 620,0 580,5 536,1 815,2 711,8
 
 
Table 3 Quality of life experienced on average by Norwegian MS-patients  
                        at EDSS-levels 1-9 (% of perfect healthy) 
 
                    EDSS 1 2 3 4 5 6 7 8 9 
Quality of life 78,2 75,1 67,3 60,8 57,5 51,3 52,6 38,5 20,0 
 
 
                                                 
1 In our work, we have had to utilize information from partly differing time periods. The information has, 
   however, been treated and used so to reflect the situation in 2002 reasonably well 
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Table 1 gives a conservative estimate of the total yearly cost of MS to the Norwegian 
society around year 2002 of NOK 1 836 millions, and a best estimate of NOK 4 033 
millions, more that twice as large. The direct economic cost contains the cost of all the 
resources, human as well as physical, used to diagnose, treat and nurse etc., or to give 
other forms of help or support MS-patients because of their illness. The indirect 
economic cost contains all the potential generation of welfare lost due MS-patients´ 
reduced participation in paid work, and the socioeconomic cost the cost to society due to 
the patients´ reduced ability to perform also unpaid work, and to pain, grief, anxiety and 
social handicaps caused by MS. Table 2 and 3 show how the total yearly cost to society 
per MS-patient, and the patients experienced quality of life, on average varied with 
illness severity. 
 
 
Arriving at the results 
 
Drug costs 
 
MS-patients use a variety of drugs because of their illness. From a cost perspective the 
absolute most important are β-interferons and glatiramer acetate. These drugs are used by 
MS-patients only, and the sales are surveyed by both the Norwegian National Insurance 
Administration and The Norwegian Association of Pharmaceutical Manufacturers. 
Especially the information from the manufacturers´ association may, after a few routine 
adjustments, mainly by replacing the wholesale prices used in their statistics with retail 
prices, be said to give very close to ideal information on the cost to society of the use of 
these drugs. When we made our study the most recent information from the 
manufacturers´ association was for 2001. This information on the cost of β-interferons 
and glatiramer acetate was used, after the mentioned replacement of prices, as our 
conservative estimate of the cost of immunomodulatory drugs.  To arrive at the best 
estimate, we increased our conservative estimate by 50 % because the information from 
both the Norwegian National Insurance Administration and The Norwegian Association 
of Pharmaceutical Manufacturers showed that the use of β-interferons and glatiramer-
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acetate absolutely were on the rise and that we had not seen what might be expected to be 
the full use of these drugs yet. 
 
For two of the remaining drugs used by MS-patients because of their illness, Solumedrol 
and Prednisolon, we gathered information on the volume components of their cost to 
society through the survey among the MS-patients in Hordaland and from hospital 
records. The information from the hospitals indicated less use of these drugs than the 
information from the postal survey. The information from the hospitals should in 
principle be routine recorded and should therefore also in principle be more ideal than the 
survey information. It was therefore used for the conservative estimates of the volume 
components of the cost to society of the use of the drugs. The information from the 
hospitals was however far from complete and we therefore used the information from the 
postal survey for the best estimates. The Norwegian Pharmaceutical Product 
Compendium (Felleskatalogen, 2002) gives retail prices for drug sales in Norway. We 
considered these prices to give reasonably ideal information on the cost to society of each 
unit of the drugs, and applied them unadjusted as both conservative and best estimates of 
the value components. 
 
For all other drugs used by MS-patients due their illness, we gathered information on the 
cost of their use to the Norwegian society mainly through the postal survey. Information 
gathered in this way may not come especially close to ideal, but it seemed to be the only 
feasible way to gather it. For drugs where the patients´ outlays could be assumed to 
reflect the cost of their use to society, possibly after some routine adjustments, we asked 
for this information directly in the survey. For drugs where the patients´ outlays could not 
be assumed to reflect the cost to society of the use because of subsidies etc., we gathered 
only information on the volume components through the postal survey, and used 
information in Felleskatalogen to estimate the value components in the same way as for 
Solumedrol and Prednisolon. We made no attempt to differentiate between conservative 
and best estimates for the information on the use of all these unspecified drugs, and the 
difference between the conservative and best estimates of the total cost to society of the 
use of the drugs is therefore solely due to the extrapolation process where we used the 
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conservative estimate for the relevant national patient population to arrive at the 
conservative estimates of the cost, and the best estimate for the relevant national patient 
population to arrive at the best estimates of the cost. Table 4 summarizes the estimates of 
the cost to society of MS-patients´ use of drugs due to their illness. 
 
 
Table 4 Total yearly cost to the Norwegian society of drug use due to MS 
  around year 2002 
                
  Conservative estimates Best estimates 
 
 
Drug: 
Volume-
compo-
nents 
Value-
compo-
nents 
Cost to 
society 
Volume-
compo-
nents 
Value- 
compo-
nents 
Cost to 
society 
 
Solumedrol 
 
870 690 600 000 1 390
 
690 959 000
 
Prednisolon 
 
870 136 118 000 1 390
 
148 206 000
Β-interferon/ 
glatiramer 
acetate 
 
Without 
meaning 
Without
meaning 165 000 000
Without
meaning
 
Without 
meaning 248 000 000
Other drugs 
bought  
at Pharmacies 
 
Without 
meaning 
Without
meaning 24 051 000
Without
meaning
 
Without 
meaning 28 685 000
Non-pharmacie 
drugs 
Without 
meaning 
Without
meaning 6 631 000
Without
meaning
Without 
meaning 7 909 000
 
Total 
 
196 400 000
 
285 759 000
 
 
The cost of ambulatory care  
 
MS-patients visit a range of professionals for consultation and treatment that do not 
require institutionalization, most often physicians, nurses and physiotherapists, but also 
occupational therapists, incontinence advisors, speech therapists, psychologists, social 
workers, social welfare workers, opticians, chiropodists, acupuncturists, homeopaths, 
ergo therapists, chiropractors, healers and foot zone therapists mainly. We found no 
information that could be said to come especially close to ideal for the setting of 
numerical targets for the volume components of the cost to the Norwegian society of 
these visits. 
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 We chose to gather most of the information on the volume components through the 
survey among the MS-patients in Hordaland County. Here we asked the patients for the 
number of visits they had made to each category of professionals the last month. For 
polyclinic visits to neurologists in hospitals, we gathered in addition information on the 
volume components from the Norwegian Patient Register. This information should in 
principle be routine recorded and should therefore also in principle be more ideal for the 
setting of numerical cost targets than information from the survey. It seemed, however, to 
be somewhat incomplete. For visits to physicians in general, some information was also 
available from an earlier attempt to set a numerical target for the cost of MS-to the 
Norwegian society (Fuglset and Mehling, 1996). 
 
The information gathered through the postal survey on polyclinic visits to neurologists in 
hospitals indicated a higher number of such visits than the information from the 
Norwegian Patient Register, and even still higher than the information in Fuglset and 
Mehling´s study. The information in Fuglset and Mehling´s study was based on very 
simplifying assumptions, however, and we used the information from the Norwegian 
Patient Register, which was somewhat mid-way between the information gathered 
through the postal survey and the information in Fuglset and Mehling´s study, as our 
conservative estimate of the volume component of the cost to the Norwegian society of 
these visits. As our best estimate, we used the best estimate based on the information 
from the postal survey. For visits to physicians in private practice, even the conservative 
estimate based on the information gathered through the postal survey was more than four 
times higher than the estimate in Fuglset and Mehling´s study. Because of this, we chose 
the conservative estimate of the volume component of the cost of visits to or by 
physicians in private practice as 50 % of the conservative estimate based on the results 
from the postal survey. As our best estimate, we used the best estimate based on the 
information from the postal survey unadjusted. For all other visits, we based both our 
conservative and best estimates of the volume component of their cost to society on the 
information from the survey. The difference between the estimates also here being due 
solely to the extrapolation process where we used the conservative estimate for the 
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relevant national patient population to arrive at the conservative estimates of the volume 
component, and the best estimate for the relevant national patient population to arrive at 
the best estimate of the volume component. 
 
While we found no information that could be said to come especially close to ideal for 
the setting of numerical targets for the volume components of the cost to society of MS-
caused ambulatory care, for the value components, the picture was more mixed. For the 
value components of the costs to society of the visits to physicians, psychologists and 
physiotherapists, we could use information in official price- or tariff lists for services 
typically provided during such visits, negotiated between Norwegian health authorities, 
and hospitals and the professionals´ organizations. The listed prices and tariffs were 
exclusive of sales tax, and we considered them to give reasonably close to ideal 
information on the value components of the cost to society of visits to psychologists, 
physiotherapists and doctors in private practice. For polyclinic visits to neurologists in 
hospitals, however, they seemed to be somewhat farther from ideal, because the 
negotiation of this tariff is complicated both by political considerations and defective 
information availability. Bearing this in mind, we set the conservative estimates like the 
prices/tariffs of short and uncomplicated visits. We set the best estimates as weighted 
averages of the prices and tariffs for visits of varying content and duration, assumed to be 
typical for MS-patients. We assumed the value components of the cost to society for the 
rest of the visits, which together accounted for only 26 % of the number of visits to 
physiotherapists, to be identical to the value components of the cost of visits to 
physiotherapists, except for the visits to or by nurses. The value components of the cost 
of visits to or by nurses were estimated from information on nurses´ salaries, typical 
health-sector overhead costs, and duration of visits. For home visits, transport costs were 
also included. More information on the volume- and value components and the total cost 
to society of ambulatory care due to MS is given in table 5. 
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Table 5 Conservative and best estimates of the yearly cost to the Norwegian 
society of ambulatory care due to MS around year 2002  
 
 
  Conservative estimates   Best estimates  
 
Visits: 
Value-
compo-
nents 
Volume-
compo-
nents 
Cost to 
society 
Value-
compo-
nents 
Volume-
compo-
nents 
Cost to 
society 
To/by physicians in private 
practice: 
      
General practitioners 224 7 705 1 726 000 344 18 380 6 323 000 
Specialists 201 1 635 329 000 326 3 900 1 271 000 
Home visits 639 935  597 000 770 2 230 1 717 000 
Contact by telephone etc. 35 3 200 112 000 35 7 800 273 000 
Sum physicians in private 
practice: 
  
13 475 
 
2 764 000 
  
32 310 
 
9 584 000 
 
Neurologists in hospitals 
 
175 
 
6 085 1 065 000 
 
605 
 
10 000 6 050 000 
 
Sum physicians 
  
19 560 
 
3 829 000 
  
42 310 
 
15 634 000 
       
To/by nurses:       
Home visits 213 275 630 58 709 000 320 328 630 75 585 000 
At nurses´ office 128 9 810 1 256 000 170 11 700 1 989 000 
Contact by telephone etc. 43 9 340 402 000 57 11 140 635 000 
 
Sum nurses 
  
294 680 
 
60 367 000 
  
351 470  
 
78 209 000 
       
To other professionals:       
Physiotherapists 235 135 430 31 826 000 300 161 530 48 450 000 
Occupational therapists 235 4 200 987 000 300 5 010 1 503 000 
Incontinence advisors 235 930 219 000 300 1 110 333 000 
Speech therapists 235 930 219 000 300 1 110 333 000 
Psychologists 245 3 270 801 000 386 3 900 1 505 000 
Social welfare workers 235 470 110 000 300 560 168 000 
Social workers 235 1 870 439 000 300 2 230 669 000 
Opticians 235 4 670 1 097 000 300 5 570 1 671 000 
Chiropodist 235 6 540 1 537 000 300 7 800 2 340 000 
Acupuncturists 235 7 940 1 866 000 300 9 250 2 775 000 
Homeopaths 235 1 400 329 000 300 1 670 501 000 
Ergo therapists 235 2 360 555 000 300 2 790 837 000 
Chiropractors 235 470 110 000 300 560 168 000 
Healers 235 930 219 000 300 1 110 333 000 
Sone therapists 235 470 110 000 300 560 168 000 
Various other professionals  235 1 870 439 000 300 2 230 669 000 
 
Sum other professionals 
  
173 750 
 
40 863 000 
  
206 990 
 
62 432 000 
       
Total  487 990 105 059 000  600 000 156 275 000 
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Cost of institutionalization 
 
Institutionalization of MS-patients because of their MS takes mainly three forms, hospital 
stays, nursing-home stays and stays at rehabilitation centers. The hospital stays are either 
day-and-night stays, denoted “bed-days” in this article, or stays only during daytime, 
denoted “day-stays”. Information on the volume components of the cost to the 
Norwegian society of the hospital stays should in principle be routine recorded by the 
Norwegian Patient Register. Further, much effort is made by a related organization unit, 
Samdata, to estimate the corresponding unit costs. Therefore, information that should 
come reasonably close to ideal for the setting a numerical target for the cost to society of 
these stays should in principle exist. It turned out, however, that this information lacked 
somewhat in reliability. Therefore, we also gathered supplementing information through 
the postal survey among the MS-patients in Hordaland County.  
 
The information from the Norwegian Patient Register on both bed-days and day-stays in 
hospitals indicated a lower number of such stays than the information from the survey. 
For bed-days the differences were in the area 25 % to 50 %. Since information from the 
survey was gathered from a convenience sample, we made checks to see whether there 
could be any obvious fallacies in this information. We found no such fallacies, and we 
chose the best estimate of the volume component of the cost to the Norwegian society of 
these stays mid-way between the number of bed-days indicated by the information from 
the Norwegian Patient Register, and the best estimate of this number based on the 
information from the survey. We chose he information from the Norwegian Patient 
Register as it was for our conservative estimate. For day-stays the information from the 
two sources was more dramatically different. The information from the survey indicated 
a number of day-stays more than ten times higher than the number indicated by the 
information from the Norwegian Patient Register. Further checks on the information from 
both sources indicated important weaknesses of both. Therefore, we chose the 
conservative and best estimates of the volume component of the cost to society of MS-
patients´ day-stays in hospitals mid-way between the number of such stays indicated by 
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the information from the Norwegian Patient Register, and the conservative and best 
estimates, respectively, based on the information from the survey. 
 
We collected information on unit costs of MS-patients´ bed-days in hospitals mainly from 
the National Insurance Administration, but also checked it against information from 
Samdata. Both the National Insurance Administration and Samdata have put much effort 
in trying to set a numerical target for this cost, and their information on this topic may 
therefore be said to come reasonably close to ideal, even if not perfect due to some 
weakness in the basic data for their calculations. The information from the two sources 
corresponded reasonably well. The information from the National Insurance 
Administration, however, appeared to fit our needs best and we therefore used this both 
as conservative and best estimates of the value component of the cost to society of bed-
days in hospitals due to MS. We found no information on the unit cost of day-stays, and 
assumed somewhat arbitrarily, the value component of their cost to society to be 1/3 of 
the cost of bed-days. 
 
For stays in nursing homes and rehabilitation centers, in our opinion no sources of 
information appeared to exist, that could give even close to ideal information for the 
setting of numerical targets for their cost to society. We therefore found we would have 
to rely on less satisfactory information sources, and we considered the best alternative to 
be to try to gather information on the volume components of the cost through the survey 
among MS-patients in Hordaland. For stays in rehabilitation centers, this information 
could also be checked roughly against information gathered by the Norwegian Patient 
Register. The information from the patient register seemed to confirm the information 
gathered through the postal survey reasonably well, and we therefore chose the 
conservative and best estimates based on the information gathered through the postal 
survey, unadjusted as estimates of the volume components of the cost to the Norwegian 
society of both nursing home and rehabilitation center stays. Our estimates of the value 
components were solely rough assumptions based on information from different sources 
touching on the theme. Table 6 summarizes the information on the cost to the Norwegian 
society of institutionalization due to MS. 
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 Table 6 Conservative and best estimates of the yearly cost of hospital stays, 
 nursing-home stays and stays at rehabilitation centres to the 
 Norwegian society around year 2002   
         
  Conservative estimate Best estimate 
 
 
Stays at: 
Volume-
compo-
nents 
Value-
compo-
nents 
Cost to 
society 
Volume-
compo-
nents 
Value-
compo-
nents 
Cost to 
society 
Hospitals as: 
Bed-days 
Day-stays 
 
5 970 
1 760 
7 450
2 480
44 477 000
4 365 000
7 475
2 080
 
7 450 
2 480 
55 689 000
5 158 00
Nursing 
homes 
 
60 710 1 275 77 405 000 72 410
 
1 500 108 615 000
Rehabilitation 
centers 
 
32 690 
 
4 475 146 288 000 38 990
 
4 475 174 480 000
 
Total 
 
272 535 000
 
343 942 000
 
 
 
Cost of support and assistance   
 
Many MS-patients are in need of assistance and support for the carrying out of daily 
activities. This can be given directly as human assistance in the carrying out of the 
activities, and more indirectly as equipment and adaptations that may make it easier for 
the patients to carry out the activities themselves. Setting a numerical target for the cost 
to the Norwegian society of this assistance, equipment and adaptations poses special 
problems, especially for equipment and adaptations. 
 
 
Equipment and adaptations 
We found no existing sources that contained information that might be said to come even 
close to ideal for the setting of a numerical target for the cost to the Norwegian society of 
equipment and adaptations for MS-patients. The information would, in our opinion, also 
be difficult to procure more directly, because the equipment and adaptations will often be 
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tailored to the individual patients. We found our best alternative, though, to be to try to 
gather somewhat rough information on the volume components of the cost of equipment 
and adaptations in two ways, both through the survey among the MS-patients in 
Hordaland, and also by eliciting expert opinions, and combine this information with 
similarly rough information on the value components. In the survey, we asked the 
patients for the number of units they had received or bought the last 12 months within 
broad categories of equipment and adaptations. We extrapolated this information to 
conservative and best estimates of the volume components of the cost to the Norwegian 
society of the equipment and adaptations, using the conservative and best estimates of the 
size of the relevant national patient population. However, since each patient typically will 
receive much of such equipment and adaptations only once, or very few times during 
their lifetime, if at all, that may specifically reduce the reliability of information procured 
as described above, where a prevalence approach was used. Therefore, we also attempted 
to use an incidence approach. We asked two neurologists, two ergotherapists and one 
nurse, all with expert knowledge of the effects of MS, to give their judgment of how large 
percentage of persons hit by MS would be in need of the different kinds of equipment and 
adaptations during their life-time, and if so also of how many units they might need. They 
were asked to give both conservative and their best estimates. Three would not answer 
the question, claiming that it would be an impossible task. Two, however, the nurse and 
one of the ergotherapists, joined forces and gave their common estimates. Because of the 
limited response to this attempt to gather information on the volume components of the 
cost to the Norwegian society of equipment and adaptations for MS-patients, we chose 
not to use the information received through this request in our attempt to set a numerical 
target for the cost to the Norwegian society of equipment and adaptations. It should be 
noted however, that the information gathered through the experts´ opinions was 
dramatically different from that given in the responses to the survey among the MS-
patients in Hordaland County. 
 
To arrive at the value components of the cost, we chose to assume that the cost of 
construed standard units within each of the specified categories of equipment and 
adaptations, would to be representative for the costs of units typically provided to MS-
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patients, and we attempted to estimate this cost mainly from information in the previously 
mentioned study on the cost of MS in Sweden (Henriksson, 2001). To some extent, 
though, this information was also supplemented with information on corresponding 
Norwegian prices in 2002. Comparisons indicated that Norwegian 2002 NOK-prices 
typically could be as much as 50 % higher than the 1998 SEK-prices given in the 
Swedish study. Based on this information, for most of the equipment and adaptations, we 
used the SEK costs as conservative estimates of the cost to the Norwegian society of 
equipment and adaptations for MS-patients around 2002 because the combined effect of 
currency translation and Norwegian inflation from 1998 to 2002 seemed to “cancel each 
other out”. For our best estimates, we increased the Swedish 1998 SEK prices by 50 %. 
 
 
Human assistance 
In addition to equipment and adaptations that may make it easier for patients to carry out 
daily activities themselves, MS-patients may also receive human assistance directly for 
the carrying out of the activities. This may be assistance that is paid for from 
professionals, mainly personal assistants, home helpers and babysitters, and unpaid 
assistance mainly from relatives and friends. We found no existing sources that contained 
information that could be said to come close to ideal for the setting numerical targets for 
the volume components of the cost to the Norwegian society of this assistance. We chose 
to provide also this information through the survey among the MS-patients in Hordaland 
County. Here we asked the patients how many hours of paid help and assistance of the 
different kinds they had received last month. Concerning help and assistance from 
relatives and friends, we also asked whether relatives or friends had had reduced posts, 
and if so, the percentage reduction, and if they had had short term absences from work or 
used their spare time, and also if so, how many hours, to provide the assistance. We 
arrived at our conservative and best estimates of the volume components of the cost to 
society of the help and assistance, measured as lost work-years for reduced posts, and 
hours for short term absences and use of spare time, by extrapolating this information 
using the conservative and best estimates of the relevant national MS-population. 
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When we chose to use work-years and hours like this as the unit of measurement for the 
volume component of the cost to the Norwegian society of the help and assistance, we 
could also extract information on some of the value components, that might be said to 
come reasonably close to ideal, from wage- and labor cost information, routine gathered 
by the Norwegian Bureau of Census. This concerned mainly the value components of the 
cost to society of paid assistance and assistance from relatives and friends during time 
they would else have used to perform paid work.  
 
The information from the Norwegian Bureau of Census indicated, however, that females 
performed fewer hours of paid work daily than males, and were also less productive the 
hours they performed such work. To arrive at conservative estimates, we assumed that 
these differences reflected real differences in productivity. To arrive at the best estimate, 
however, we assumed that the differences in productivity between sexes indicated by the 
information from Norwegian Bureau of Census did not reflect real differences in 
productivity, but were caused by females typically performing more unpaid work, 
especially at home, than males. Therefore, for our best estimates, we assumed that the 
bureau of census´ wage- and labor costs for males reflected also females´ productivity. 
This explains why the conservative and best estimates of the cost of relatives´ and 
friends´ help and assistance differs more for females than for males.  This way of taking 
care of females performing more unpaid work than males may deviate somewhat from 
how this is more typically handled in cost-of-illness studies, where reductions in 
performance of unpaid work, like house-keeping and child-rising etc., is often treated as a 
cost category of its own. This may be principally more correct, but will not affect the 
estimated total costs to society. Further, introducing reductions in unpaid work as a cost 
category of its own may also necessitate more speculative assumptions to arrive at the 
final estimates of total costs to society. For the best estimates of the cost to society of 
relatives´ and friends´ help and assistance to MS-patients during spare time, we assumed 
that the wage- and labor costs for males reflected the unit cost to the Norwegian society, 
also of this help and assistance. For the conservative estimate of this cost, the cost to 
society was assumed to be zero. More detail on the setting of the numerical targets set is 
given in table 7. 
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Table 7 Conservative and best estimates for the yearly cost to the Norwegian society  of support 
  and assistance to MS-patients around year 2002 
         
  Conservative estimates   Best estimates  
 Volume-
compo-
nents 
Value-
compo-
nents 
Cost to 
society 
Volume-
compo-
nents 
Value-
compo-
nents 
Cost to 
society 
Adaptations       
Adaptation of kitchen 98 30 000 2 940 000 117 45 000 5 265 000 
Adaptation of bathroom 234 30 000 7 020 000 279 45 000 12 555 000 
Ramps 145 10 000 1 450 000 173 15 000 2 595 000 
Roof lift 56 25 000 1 400 000 67 37 500 2 513 000 
Stair- or pit lift 79 75 000 5 925 000 95 112 500 10 688 000 
Other adaptations of house 243 30 000 7 290 000 290 45 000 13 050 000 
Safety alarm 163 5 000 815 000 195 7 500 1 463 000 
Adaptation of car 285 130 000 37 050 000 334 195 000 65 130 000 
Adaptation on the job 145 30 000 4 350 000 173 45 000 7 785 000 
Sum adaptations   68 240 000   121 044 000 
Equipment       
Wheelchair 509 6 000 3 054 000 607 9 000 5 463 000 
Electric wheelchair 388 110 000 42 680 000 462 165 000 76 230 000 
Elektric moped 145 30 000 4 350 000 173 45 000 7 785 000 
Rollator 220 1 000 220 000 262 1 500 393 000 
Special furniture 121 10 000 1 210 000 145 15 000 2 175 000 
IT equipment 42 10 000 420 000 50 15 000 750 000 
Surgical splints etc. 84 400 34 000 100 600 60 000 
Walking stick/crutch 616 100 62 000 735 150 110 000 
Special kitchen devices 201 2 000 402 000 240 3 000 720 000 
Special writing devices 131 2 000 262 000 156 3 000 468 000 
Other minor equipment 22 2 000 44 000 26 2 000 52 000 
Sum equipmentr   52 738 000   94 206 000 
Paid assistance       
Personal assistant 126 090 272 34 296 000 150 390  390 58 652 000 
Support worker 9 340 272 2 540 000 11 140  390 4 345 000 
Home care 116 750 298 34 792 000 139 250 490 68 233 000 
Domestic help 4 670 298 1 392 000 5 570 490 2 729 000 
Child care 65 380 272 17 783 000 77 980 390 30 412 000 
Unspecified paid assistance 4 670 272 1 270 000 5 570 390 2 172 000 
Transport - 410 970 85 - 34 932 000 - 490 160 150 - 73 524 000 
Sum paid assistance   57 141 000   93 019 000 
Unpaid assistance from 
relatives and friends, in form 
of relatives´ and friends´:  
      
Sick absence form work:       
Women  4 600 1 283 5 902 000 5 490 1 778 9 761 000 
Men 14 180 1 778 25 212 000 16 910 1 778 30 066 000 
Reduced posts       
Women 35 295 200 10 332 000 42 408 000 17 136 000 
Men   62 408 000 25 296 000 74 408 000 30 192 000 
Spare time used 948 010 0 0 1 130 710 237 267 978 000 
Sum unpaid assistance   66 742 000   355 133 000 
       
Total   244 861 000   663 402 000 
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 The cost of MS-patients reduced participation in paid work 
 
MS may cause not only the patients´ relatives and friends, but even more the patients 
themselves of course, to reduce their participation in paid work. These reductions will 
mainly take the form of short term sick absences from work, absences because of 
rehabilitation, reduced posts, early retirement or reductions due to premature death 
because of MS. Information on work-days lost because of short term sick absences and 
absences due to rehabilitation, and on work-years lost because of reduced posts and early 
retirement is routine recorded by the National Insurance Administration for the part of the 
reductions reimbursed by them. We considered that this information, with a few routine 
adjustments, could be transformed to information on the volume component of the cost to 
the Norwegian society of the reductions. The value components would be similar to the 
value components in the preceding paragraph of the cost to society of relatives´ and 
friends´ reduced participation in paid work. This combined information on the volume- 
and value components of the cost to the Norwegian society due to MS-patients reduced 
participation in paid work might, at least in principle, be said to be reasonably ideal for 
the setting of a numerical target for the cost. We also gathered information on the volume 
components, however, through the postal survey among the MS-patients in Hordaland 
County. It turned out that with one exception the numbers derived from the information 
from The National Insurance Administration were markedly higher than the numbers 
derived from the survey. In these cases, we used the numbers derived from the 
information from The National Health Administration as conservative estimates of the 
volume components, while we chose the best estimates mid-may between these 
conservative estimates and the best estimates derived from the information in the postal 
survey.   
 
The information from The National Insurance Administration did not cover information 
on reductions in paid work due to premature death because of MS. Neither would it, for 
obvious reasons, be possible to gather such information through the postal survey among 
MS-patients in Hordaland County. Some information on these reductions, that might be 
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used to estimate the volume component of the cost to society is gathered by the 
Norwegian Bureau of Census, but does not cover the relevant time span completely. In 
addition, the information seems to be somewhat incomplete also for the part of the time 
span covered, especially for the first part. Since the information from The Bureau of 
Census, however, was the only information that seemed to exist on this topic, we used 
this information with only a marginal upward adjustment as both conservative and best 
estimates of the volume component of the cost to the Norwegian society of the reductions 
in paid work due to premature death because of MS. As the best estimate of the value 
component of the cost, we used the same information as for the value component of the 
cost to society of relatives working in reduced posts. As the conservative estimate, zero 
was chosen since it can be argued that people in general will consume approximately the 
values they create during their lifetime. Table 8 gives details. 
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Table 8  Conservative and best estimates for the yearly cost of MS-patients 
 reduced performance of paid work to the Norwegian society 
 around year 2002 
  
  Conservative estimate   Best estimate  
 
Reduced performance of 
paid work due to: 
Value-
compo-
nents 
Volume-
compo-
nents 
Cost to 
society 
Value-
compo-
nents 
Volume-
compo-
nents 
Cost to society 
 
Sick absence from work 
      
Women 1 283 40 000 51 320 000 1 778 73 000 129 794 000 
Men 1 778 30 000 53 340 000 1 778 37 000 65 786 000 
Sum sick absence from work  70 000 104 660 000  110 000 195 580 000 
 
Rehabilitation: 
      
Women 1 283 5 200 6 672 000 1 778 12 000 21 336 000 
Men 1 778 6 000 10 668 000 1 778 6 000 10 668 000 
Sum rehabilitation  11 200 17 340 000  18 000 32 004 000 
 
Reduced post/early retirement 
      
Women 295 200 1 905 562 356 000 408 000 2 600 1 060 800 000 
Men 408 000 815 332 520 000 408 000 1 000 408 000 000 
Sum reduced posts and early 
retirement 
 
2 720 
 
844 876 000 
  
3 600 
 
1 468 800 000 
 
Premature death due to MS 0 - 
 
- 408 000 
 
524 
 
213 792 000 
 
Total 
  
1 016 876 000 
  
1 910 176 000 
 
 
Socioeconomic costs 
     
In addition to the effect MS may have for the patients´ ability to perform paid work, the 
illness may also reduce their ability to perform unpaid work like housekeeping, bringing 
up children and so on, and to perform leisure activities. The patients may further 
experience pain and both the patients and their relatives may have worries because of the 
patients´ illness. We have considered this last group of effects as reductions in the 
patients´ and relatives´ experienced quality of life, and the cost to society due to these 
reductions as a socioeconomic cost, in line with the choice described in the paragraph on 
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support and assistance to MS-patients, of not treating reductions in unpaid work as a cost 
category of its own. 
 
We could not find any information that could be said to be ideal or close to ideal, neither 
on the volume- nor on the value components of the cost to the Norwegian society of these 
reductions in quality of life. We considered the best alternative to be to gather the 
information for the volume component of the cost through the postal survey among the 
MS-patients in Hordaland County, and for the value components from other cost-of-
illness studies. In the postal survey, we asked the patients to indicate on a visual analogue 
scale how they would characterize their own health situation compared to what they 
would consider “perfectly healthy”. The distance they indicated from “100 % perfectly 
healthy” was interpreted as their felt percentage reduction in quality of life. From this 
reduction, we deducted the reduced quality of life normally felt by adult persons, and 
assumed the remaining differences to represent the patients´ loss in quality of life because 
of their MS (Canadian Burden of Illness group, 1998). We arrived at conservative and 
best estimates of the volume component of the cost to the Norwegian society of the 
reduced quality of life by applying this percentage to the conservative and best estimates 
of the relevant national patient population, giving quality-adjusted life-years lost as the 
result. In addition, we added 10 % to account approximately for relatives´ reduced quality 
of life due to the patients´ illness. 
 
As our best estimate of the value component of the cost, we chose a value given as 
typical in the Swedish cost of MS study by Henriksson et al.. We set the conservative 
estimate to zero both for the patients and their relatives because of the enormous 
uncertainty attached to estimates of the economic value of quality of life, and also 
because there is much disagreement on whether losses of quality of life should be 
regarded as a cost to society. 
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Table  9 Conservative and best estimates of the total yearly socioeconomic 
  cost to Norway due to MS around year 2002 
 
 
  Conservative estimates Best estimates 
 Volume-
compo-
nents 
Value-
compo-
nents 
Cost to 
society 
Volume-
compo-
nents 
Value-
compo-
nents 
Cost to 
society 
 
Patients 
 
0 0 0 1 225
 
500 000 612 500 000
Relatives 0 0 0 123 500 000 61 250 000
Total 0 0 0 1 348 500 000 673 750 000
 
 
Costs, quality of life and disease severity  
 
To relate the per patient costs and Norwegian MS-patients experienced quality of life to 
the severity of their disease, disease severity was expressed by patients´ EDSS-levels, and 
whether they had experienced a relapse or not. We could gather information on the 
patients´ EDSS-levels from the Multiple Sclerosis National Register for 400 of the 
patients who answered the survey among the MS-patients in Hordaland County, and 
information on the occurrences of relapses, costs and patients experienced quality of life 
through the survey among MS-patients in Hordaland County ,as described above. Table 
9, 10 and 11 show the average experienced quality of life and costs per patient in the 
relevant patient population, for the patients at each EDSS-level from 1-9, and the 
additional cost of relapses.  In table 10, direct economic cost is exclusive cost of 
immunomodulatory drugs, but aside from that includes the cost of all the resources, 
human as well as physical, used to diagnose, treat and nurse etc., or to give other forms of 
help or support MS-patients because of their illness. The indirect economic cost contains 
all the potential generation of welfare lost due MS-patients´ reduced participation in paid 
work, and the socioeconomic cost the cost to society due to the patients´ reduced ability 
to perform also unpaid work, and to pain, grief, anxiety and social handicaps caused by 
MS. The information on the cost of MS to the Norwegian society in general was, as 
described in the first part of this article, gathered from a wide range of sources to provide 
the best impression of this cost. To relate the cost information to illness severity, we 
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needed cost information on individual patients. This had to be gathered solely through the 
survey among the MS-patients in Hordaland County. Therefore there is not 100 % 
correspondence between the cost figures in table 1 and table 10 and 11. The reason that 
the cost of immunomodulatory drugs is not included in the numbers in table 10 is that this 
information is planned to be used in our further work to analyze the cost-utility of the use 
of these drugs. There the cost of these drugs has to be treated separately.  
 
 
Table 9 Quality of life experienced on average by Norwegian patients in the 
                        relevant patient population, at EDSS-levels 1-9 (percent of  “perfect 
                        healthy”) 
 
EDSS 1 2 3 4 5 6 7 8 9 
Experienced 
quality of life 
78,2 75,1 67,3 60,8 57,5 51,3 52,6 38,2 20,0 
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Table 10 Average direct economic cost, total economic cost and total cost  
                        to society per patient in the relevant patient population, at  
                        EDSS-levels 1-9 around 2002 (NOK 1000) 
 
                EDSS 
Estimates 
1 2 3 4 5 6 7 8 9 
Direct economic 
cost 
         
Best 105,2 102,2 184,7 212,0 376,7 375,8 344,9 656,5 552,3 
Conservative 103,2 99,7 169,9 199,6 338,1 329,5 271,0 503,5 386,5 
+ Indirect 
   economic cost: 
   
Best 159,7 165,7 249,6 280,1 352,1 314,7 332,4 391,0 408,0 
Conservative 129,8 134,7 200,9 224,6 281,8 251,1 265,1 311,7 325,3 
= Total  
   economic cost 
         
Best 265,0 268,0 434,3 492,1 728,8 690,5 677,3 1 047,5 960,3 
Conservative  233,1 234,3 370,8 424,2 620,0 580,5 536,1 815,2 711,8 
+ Socioeconomic 
   Cost 
         
Best 117,4 134,5 162,5 195,0 210,3 247,1 207,6 307,2 275,0 
Conservative 0 0 0 0 0 0 0 0 0 
= Total cost to 
    society 
         
Best 382,4 402,5 596,8 687,0 939,1 937,6 884,9 1 354,7 1 235,3 
Conservative 233,1 234,3 370,8 424,2 620,0 580,5 536,1 815,2 711,8 
  
 
In addition to the averages given in tables 9 and 10, we also performed several 
regressions to try to find underlying patterns in the data material. These indicated a rather 
close to linear relation between the patients EDSS-levels, and the total cost per patient to 
society and patients experienced quality of life. For the direct economic cost, the relation 
was more of an exponential kind. The differences are explained by both indirect 
economic and socioeconomic costs exhibiting relatively steep rises at low EDSS-levels, 
and then flattening more out. 
 
We estimated the cost of a relapse as the difference in average monthly costs between 
patients with and without relapse. Table 11 gives the results. 
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Table 11 Cost of a relapse around 2002 (NOK)  
 
 
Cost category 
Patients with 
relapse 
Patients without 
relapse 
Difference 
Direct economic cost 
Best 24 975 20 329 4 646
Conservative 22 901 17 677 5 224
Total economic cost 
Best 51 993 40 986 10 007
Conservative 44 632 34 229 10 403
Total cost to society 
Best 72 692 55 578 17 114
Conservative 44 632 34 229 10 403
 
 
Experienced quality of life differed with 0,12 on the visual analogue scale (0,54 versus 
0,66) between those experiencing a relapse and those not. 
 
 
Comparisons with Sweden 
 
The questionnaire we used in our study was structured so to facilitate comparisons of our 
results with the results obtained for Sweden in the study on the cost of MS to the Swedish 
society in 1998 (Henriksson et al., 2001). Their study was of special interest to us since it 
was for our closest neighboring country and also seemed to have been carried out in a 
way that corresponded well with the way we planned to arrive at our best cost estimates. 
Because of differences in the size of the two countries, costs per patient had to be 
compared. Henriksson et al. arrived at their per patient costs by dividing the national 
costs with the assumed number of persons in the total MS-population in Sweden - (not 
the relevant patient population). To arrive at comparable Norwegian figures we had to do 
the same. 
 
 30
Our best estimate of the total cost of MS to the Norwegian society around 2002 was  
NOK 4 033 million. Divided with our best estimate of the total Norwegian MS-
population, 7 740 patients, this gave approximately NOK 521 000 per patient. Henriksson 
et al. found the Swedish total cost per patient to be SEK 688 136 in 1998, when the cost 
of reduced quality of life was included. Adjusted for an exchange rate of approximately 
SEK 100 = NOK 95 in 1998 and Norwegian inflation of approximately 10 % from 1998 
to 2002, the Swedish SEK 1998-figures should be directly comparable to our own NOK 
2002-figures, indicating a 32 % higher cost per patient in Sweden. From a health-
economic point of view, this figure is only interesting to the extent it may reflect 
underlying real differences in the way MS-patients are taken car of, or economic 
conditions in the two countries. In this perspective, a closer analysis of the difference 
gives mixed results. Below, the difference is broken down to more detailed information 
on the individual subgroups of costs. 
 
 
Table 12 Cost per patient information for the main subgroups of costs in  
                         Norway and Sweden. (NOK 2002) 
 
  
Norway 
 
Sweden 
Swedish costs as % 
of Norwegian costs 
Drugs 36 920 48 455 131
Ambulatory care 20 191 33 119 164
Institutionalization 44 347 59 029 133
Support and assistance 85 711 156 287 182
MS-patients reduced 
participation in paid work * 219 299 145 577 66
Reduced quality of life 87 048 245 455 282
   
* Exclusive cost of premature death due to MS 
 
The information in table 12 shows that the difference of 32 % between the Swedish and 
Norwegian total cost per patient conceals larger differences for some such subgroups, and 
if the cost numbers in table 12 are disaggregated further, even more striking differences 
are revealed.  
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Drugs 
 
Our best estimate of Norwegian MS-patients total drug costs was NOK 285 759 000 or 
NOK 36 920 per patient. Henriksson et al. found the cost per patient to be SEK 48 445 in 
1998. Adjusted for exchange rates and inflation, this is approximately 30 % higher than 
the Norwegian number. Henriksson et al. split the drug cost in three subgroups, the cost 
of immunomodulatory drugs, other prescribed drugs and OTC-drugs. We used a slightly 
different categorization of drugs used by Norwegian MS-patients. Direct comparisons of 
the information on drug use in the two studies are therefore somewhat problematic. 
However, if the information in the studies is recasted to information on the cost of 
immunomodulatory drugs, and of all other drugs, as is done in table 13, comparisons may 
be made 
 
 
Table 13 Swedish and Norwegian drug costs per sub-group (2002 NOK)  
 Sweden Norway 
Immunomodulatary drugs 46 992 32 041 
Other drugs 1 453 4 795 
 
 
Table 13 shows that the cost of immunomodulatory drugs per patient in Sweden was 
close to NOK 15 000, or slightly less than 50% higher than in Norway. This makes the 
difference in cost to immunomodulatory drugs larger than the total difference in drug 
costs. The difference in cost to immunomodulatory drugs was, however, to some extent 
offset by NOK 3 342, or 230 % higher cost to “other drugs” in Norway.  
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Ambulatory care  
 
Our best estimate of the total cost to the Norwegian society of ambulatory care was  
NOK 156 275 000, or NOK 20 191 per patient. Henriksson et al. found the cost per 
patient in Sweden to be SEK 33 119 in 1998, close to 65 % more than in Norway, 
adjusted for exchange rates and inflation. In both studies specific information was 
gathered on the cost of visits to, or contact with a vide variety of professionals. Table 14 
shows details of the number of visits per patient and year in the two countries 1.  
 
 
Table 14 Number of visits per patient and year to ambulatory care 
practitioners in Norway and Sweden 
 
 
Ambulatory care practitioner: 
Visits of Norwegian 
MS-patients 
Visits of Swedish 
MS-patients 
Neurologist  4,1 1,8 
General practitioner 0,8 2,4 
Other specialists 0,9 - 
Physician home visit 0,1 0,3 
Nurse 9,2 1,5 
Nurse home visit 6,5 42,5 
Physiotherapist 26,4 20,9 
Occupational therapist 6,9 0,6 
Chiropodist 1,5 1,0 
Speech therapist 0,8 0,1 
Continence advisor 0,7 0,1 
Psychologist 1,1 0,5 
Social worker 2,0 0,3 
Optician 0,7 0,7 
Other paramedical practitioners 1,7 2,5 
Total 63,4 75,1 
 
The information in table 14 indicates that the by far most frequently visited ambulatory 
care practitioners in both countries were physiotherapists, and that these were visited 
somewhat more frequent in Sweden than in Norway (26,4 versus 20,9 visits per patient 
and year). The most striking difference is for nurse home visits. The average number per 
                                                 
1 The figures for Norway have been calculated from information in table 5 
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patient of such visits were 6,5 in the Swedish study and 42,5 in the Norwegian. This may 
be explained, as will be showed later, by much more extensive use of personal assistants 
in Sweden. It might be noted, though, that Swedish MS-patients seem to visit nurses in 
the nurses´ office more often than Norwegian patients (9,2 versus 1,5 visits). Swedish 
patients also seem to visit neurologists more often (4,2 versus 1,8 visits), and general 
practitioners less often (0,8 versus 2,4 visits) than Norwegian patients. In addition, 
Swedish patients seem to make much heavier use of occupational therapists than 
Norwegian (6,9 versus 0,6 visits). For visits to other ambulatory care practitioners, the 
average number of visits per patient and year were around one or less, making the 
information on the number of such visits very uncertain, and also detailed comparisons of 
little value. The average total number of visits to ambulatory care practitioners was 
slightly less than 20 % higher for the Swedish patients. The difference of 65 % in the 
average cost per patient for the total number of visits is therefore primarily caused by 
generally much higher assumed costs per visit in the Swedish study (Henriksson et al. 
2000). 
 
 
Institutionalization 
 
Our best estimate of the total cost to the Norwegian society of MS-caused 
institutionalization was NOK 44 347 per patient. In Henriksson et al.´s study the cost was 
SEK 59 047. Adjusted for exchange rates and inflation the number for Sweden is 
approximately 33 % higher than the Norwegian. There is some uncertainty, however, as 
to the comparability of these figures. The Norwegian number contains the cost of 
inpatient hospital care, rehabilitation and nursing home stays. The Swedish number 
contains inpatient hospital care and rehabilitation. The figures are only comparable to the 
extent that nursing home stays are included in the Swedish number for “rehabilitation”. If 
not, the cost of nursing home stays should be removed from the Norwegian number 
before comparisons, and if so, the Swedish number will exceed the Norwegian by close 
to 100 % (1998-SEK 59 047 versus 2002-NOK 30 404). Also some differences of even 
larger magnitudes can be found by a closer look at the underlying data for the two 
 34
countries. The average Swedish MS-patient spent 5 days a year in hospitals and close to 
20 days in rehabilitations centers. For Norwegian patients the numbers were 1,2 and 5,0 
if the number of days in nursing homes is removed from the Norwegian figure. The 
Swedish number exceeds the Norwegian by approximately 300 %. Therefore, when the 
total cost per patient number exceeds the Norwegian by less than this, the reason is that 
the unit cost numbers in the Swedish study are much lower than the Norwegian for 
inpatient hospital care and rehabilitation stays (Henriksson et al., 2000). 
 
 
Support and assistance 
 
Also when it comes to support and assistance, the Swedish estimate of the total cost to 
society exceeds the Norwegian by close to 100 %, seemingly reflecting the huge 
problems attached to estimate this cost element. The best cost estimate for Norway was 
NOK 663 402 000, or NOK 85 711 per patient. Henriksson et al. found the corresponding 
cost per patient to be SEK 156 287. However, the main part of this difference may to a 
large extent be explained by the cost of one specific kind of support, namely the cost of 
personal assistants. Leaving this cost element out, the cost per patient was NOK 78 133 
in our study and SEK 66 725 in the Swedish study, a difference of a modest 15 %, which 
might seem to be a rather close fit. But also here a closer look at the underlying 
information reveals several striking differences. The cost per patient for home help, home 
care and child care was almost 60 % higher in our study than in Henriksson et al.´s study, 
even if the number of hours of such services received was more than 100 % higher in 
Sweden. The reason is that the cost per hour of such services used in our study was three 
to four times higher than in the Swedish study. The same pattern could also be found for 
informal care, adaptations made and items purchased. The cost per patient of informal 
care according to our study exceeded the Swedish cost by more than 120 %, even if 
number of hours of such care was more than twice as large for the Swedish patients. The 
cost per hour of informal care used in our study was four to five times larger than in the 
Swedish study. For adaptations made and items purchased, the costs per unit were set  
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50 % higher in our study than in Henriksson et al.´s study. Still the total cost per patient 
of adaptations and items purchased in the Swedish study exceeded the Norwegian cost by 
more than 130 %, due to much more extensive use of adaptations and helping aids in 
Sweden. Table 15 shows the difference in the percentage of the patients receiving 
specific adaptations and helping aids in the two countries. 
 
 
Table 15 Percentage of the patients receiving adaptations and helping  
aids in Norway and Sweden 
 
 Used/made by percent of the 
patients in: 
 
Kind of adaptation/items: Sweden Norway 
Adaptation of kitchen 6 2 
Adaptation of bathroom 17 5 
Adaptations of other parts of the house 8 5 
Roof lift 8 1 
Lift 8 2 
Ramps 10 3 
Safety alarm 12 4 
Adaptations at the job 1 3 
Adaptation of the car 8 6 
Wheelchair 23 10 
Electric wheelchair 9 8 
Electric moped 10 3 
Walking stick 17 13 
Rollator 11 5 
Special kitchen utensils 11 4 
Special writing devices 6 3 
Other 13 9 
 
 
 
MS-patients reduced participation in paid work 
 
Our best estimate of the total cost of Norwegian MS-patients reduced participation in 
paid work was NOK 1 910 176 000, and NOK 246 793 per patient. Henriksson et al. 
found the corresponding cost per patient to be much lower, SEK 145 577. The Norwegian 
number includes the cost of early death because of MS with NOK 27 622. This cost was 
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not included in the Swedish study. Even adjusted for this however, the Norwegian cost 
number exceeds the Swedish by 50 %. Most of this remaining difference is due to a 
higher cost of labor used in our study (NOK 237 versus SEK 180 per hour). 
 
 
Reductions in quality of life  
 
The best estimate of the total cost of MS-patients reduced quality of life is  
NOK 673 750 000 in in our study, NOK 87 048 per patient. Henriksson et al. found the 
corresponding cost per patient to be SEK 245 455, nearly three times as large.  The cost 
per QUALY lost is identical in the two studies and the difference is solely due to greater 
MS-caused quality of life losses in the Swedish study (0,49 versus 0,17 quality-adjusted 
life years lost per patient and year). In the Norwegian number, an assumed quality of life 
loss for relatives is included. When this is removed, the Swedish number is slightly more 
than three times higher than the Norwegian. Close to 65 % of this difference is due do 
measurement method differences, in that the loss was measured  by the use of a visual 
analogue scale in our study and by combining the descriptive part of the questionnaire 
with population based quality of life values in the Swedish study. Close to another 20 % 
of the difference is explained by different corrections for normal quality of life losses felt 
in the general population, and the rest by Norwegian MS-patients reporting lower quality 
of life losses than the Swedish, as indicated in table 16. 
 
 
Costs and quality of life for various EDSS-categories 
 
The information on costs per EDSS-level from our study is given in tables 9 and 10.The 
Swedish study used broader EDSS-categories when costs and quality of life were related 
to illness severity. In tables 16 and 17 the results from our study are recasted to partly fit 
the format used by Henriksson et al. 
 
 
 37
 Table 16 MS-patients experienced quality of life in different EDSS-categories  
    in Norway and Sweden  
 
                   EDSS-level 
Studie: 
1 2 3 4 5 6 7 8 9 
Norway *) 82   71  62 
Sweden 1 68   52  17 
 
1 Henriksson et al., 2001 
*) Precise comparisons with Sweden are difficult because precise corrections for differences in the  
    patient inclusion criteria in the two studies is difficult 
 
 
 
Table 17 Total cost the Norwegian and Swedish societies, total economic  
                        and direct economic cost per patient at different EDSS levels  
                       (NOK 1000) 
 
                      EDSS 
Cost category 
≤ 3,0 3,5 -6,0 ≥ 6,5 
Total economic cost    
Norway  *) 205,8 426,7 578,7 
Sweden  **) 109,1 256,2 717,4 
Direct economic cost    
Norway  *) 79,8 212,9 323,7 
Sweden  **) 28,2 118,2 464,8 
 
*)      Precise comparisons with Sweden are difficult because precise corrections differences in the  
          patient inclusion criteria and different treatment of the cost of  interferons in the two studies 
          are difficult 
**)          Estimated from the Swedish data 
 
Even if the information for the two countries in tables 16 and 17 is far from perfectly 
comparable, some patterns still seem to emerge. The experienced quality of life is higher 
for the Norwegian patients for all EDSS categories. The Swedish numbers are lower than 
the Norwegian for low and medium, but higher for higher EDSS-levels both for or direct 
and total economic cost per patient.  
 38
We started the comparison of our own study and the Swedish study by Henriksson et al. 
by stating that our findings on the total cost to society per patient differ by 32 %, the 
Swedish numbers being the highest. The difference may be characterized as modest, 
given the uncertainty that at least as for today, surrounds all such studies. An explanation 
may however be that the Swedish study was chosen for comparison because it seemed to 
have been carried out in a way that we found sound, and that we also wanted to follow in 
our own work. Closer comparisons, however, revealed much larger differences in the 
findings on more specific cost elements, often of more than 100 %. The closeness of the 
main result may therefore very well be said to be a result of pure luck, caused by many of 
the more detailed differences canceling each other out. 
 
The Norwegian numbers may have been systematically somewhat understated, because 
of the assumption that for the patients who were excluded from the survey for ethical 
reasons, no cost would accrue to the Norwegian society because of their potential illness, 
even if the level of this understatement should hopefully be modest.   
 
 
Discussion 
 
The objective of this study has been to provide information for further economic analysis 
of the treatment of multiple sclerosis with immunomodulatory drugs. The study has 
provided information on the cost of MS to the Norwegian society in general, and on the 
cost and quality of life per patient at different EDSS-levels. Several studies have been 
carried out the last 20 years on the cost of multiple sclerosis to society. The results varies 
tremendously. For instance, in three studies on the yearly cost of an average MS-patient 
to society in Germany, United Kingdom and Sweden around 2000 the estimates varied 
from € 28 000 for UK (Kobelt et al, 2000 - I), through € 33 000 for Germany (Kobelt et 
al, 2001), and to € 45 000 for Sweden (Henriksson et al, 2001). By itself this should not 
cause concern if the estimates should be expected to reflect real differences in the costs 
between the countries. It may seem unreasonable though, that the costs should be that 
different. The clinical effects of the disease should not vary much between the countries, 
and neither do the treatment and help to the patients seem very different in general. The 
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problem is that if the estimates are not correct, but still are used for decisions that may be 
of outmost importance to the patients, as for example on treatment, these decisions may 
be quite arbitrary. The problem is further highlighted by looking at the variation in results 
over time, even within each country. For Sweden, the total yearly cost of MS to society 
was estimated to SEK 1 688 million in 1991 and SEK 1 876 million in 1994 (Henriksson, 
Jönsson, 1998), and to SEK 4 499 million in 1999 (Henriksson et al., 2001). In Germany 
it was estimated to DM 1 432 million in 1997/98 (Upmeier, Miltenburger, 2000) and to 
DM 2 977 million and DM 7 850 million in 1999 in two separate studies (Kobelt et al., 
2001), (Kobelt et al., 2000 - II), and in UK it was estimated to GBP 118 million in 
1986/87 (O´Brien, 1987), to GBP 283 million in 1993/94 (Blumhardt, Wood, 1996), to 
GBP 487 million in 1994 (Holmes et al., 1995) and to GBP 1 337 million in 1999 (Kobelt 
et al., 2000 - I). Even if it may be given good explanations for the differences, obviously 
not all the studies can have given “the truth” about the cost of multiple sclerosis in the 
three countries, and possible decisions made on the basis of the information might 
therefore not have been optimal. This is especially serious since such decisions might 
affect both the welfare and even survival of seriously ill people. One example of such 
decisions may be the different decisions made by UK and other countries´ health 
authorities on the use of β-interferons in the treatment of MS-patients during the 1990´s, 
partly on the basis of economic analyses that varied far beyond any reasonable levels 
(Jacoby et al., 1998), (Kobelt, 2000). This rise the question of how much or little 
confidence may be put in this kind of information, especially for our purpose, in Norway 
as for today. 
 
In the health-economic literature it is usually stressed that no more effort should be put 
into the gathering of data and information for health-economic analyses than will be 
reflected in a comparable increase in the value of the studies results (Drummond et al., 
2003). This is of course undisputable correct in principle. It may also be used by 
researchers, however, as an excuse to stop data search prematurely, especially since it is 
almost impossible to calculate the effect of more extensive data search on the value of the 
studies results. To try to avoid become victims of such temptations we chose a rather 
basic approach to our research question. We started by raising the question: “Concerning 
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information, how must the situation have had to be if it should have been possible to set a 
numerical target for the total cost of an illness to society 100 % correctly?” After that, the 
best answer that could be found to this question guided our work. This answer was that 
ideally, all the use of resources and all reduced generation of welfare due to the illness 
should have been routine recorded, together with their alternative values to society, 
somewhat in the same way as parts, material and mechanics´ time etc. are recorded and 
priced in car workshops. For MS, this would for instance mean that whenever a MS-
patient took an aspirin or two because of the MS this should have been recorded and 
related to MS together with the aspirins´ alternative value to society, while aspirins taken 
for other purposes should not be recorded. Similarly, if relatives had taken a day off from 
work to nurse a patient, this should have been recorded as a MS-cost, but not if they had 
dropped work for other reasons. Such recording of all use of resources and their 
alternative values to society, and all reductions in potentially welfare-generating 
activities, is of course not done systematically in any country for any illness or disease. 
Still it is done, though, for some cost elements due to some illnesses and diseases. In our 
work we made considerable effort to use such information whenever it could be found. 
Further, for cost elements where such information could not be found, the same effort 
was made to try to find information that might be expected to come as close as practically 
possible to the ideal. In addition we have tried to follow a philosophy of not excluding 
any cost element on the assumption that it would probably be of so modest magnitude 
that checking it further would be a waste of time and resources. Also, no data or 
information has been accepted to be of acceptable quality without closer evaluation. 
Finally, we have also gathered information from different sources where practical, to 
check for consistency. Still after all this effort, our results are very uncertain. 
 
Table 1 showed a conservative estimate of the total yearly cost of MS to the Norwegian 
society around year 2002 of NOK 1 836 million, and a best estimate of  NOK 4 033 
million, the best estimate being more than twice as large as the conservative. Our work 
indicates that the difference may be explained by three factors: Uncertainty on what 
elements should be included in cost-of-illness studies. For example, should “the cost of 
reduced quality-of-life be included? Uncertainty on how some cost elements should 
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valued. For example, what is the economic value of quality-of-life or leisure time? And 
finally, the combined effect of differences in information on the same phenomena in 
different sources of information, and the researchers´ choices on how to handle them. 
 
It is difficult to separate the effect of the factors 100 %. For example is the difference 
between the conservative and the best estimates of the cost of reduced quality-of-life due 
both to uncertainty on how quality-of-life should be valued economically, and on whether 
it should be included in cost-of-illness studies at all. Similarly is the difference between 
the conservative and best estimate of the cost of visits to neurologists in hospitals due 
both to differing information in different sources on the number of such visits, and on 
uncertainty on how numerical targets for the cost to society of each visit should be set. If, 
in such cases, the differences that may be attributed to two or more factors in 
combination are allocated evenly to each factor, slightly less than 50 % of the difference 
between the conservative and the best estimate of the total cost of MS to the Norwegian 
society can be said to be due to uncertainty on how cost elements should be valued, and 
slightly more than 25 % to each of the remaining two factors: uncertainty on what 
elements should be included in cost-of-illness studies and differences in information from 
different sources, and the researchers´ choices on how to handle them. 
 
Even though the part of the difference that is explained by the two first factors accounts 
for approximately 75 % of the total difference, this part of the difference may not be the 
most important from a decision making point of view. This is so because these two 
causes of uncertainty in the results are well known, and in well presented cost-of-illness 
studies there should also be clearly stated what choices have been made with respect to 
how cost elements have been evaluated and which ones are included or excluded. The 
most grave part of the difference is that which can be explained by differing information 
in different sources of information, and the researchers´ choices on how to handle them, 
since the only reason it surfaced in our study is that we had the opportunity and patience 
to gather and compare such information. Had this not been done, this uncertainty for the 
setting of a numerical target for the cost of MS to the Norwegian society would not have 
been known, and decision makers might have run the risk of using incorrect information 
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as a basis for their decisions without being aware of it. Decision makers would probably 
have put the same confidence in numbers “collected through a postal survey among a 
sample comprising 10 % of the total national patient population”, especially when also 
assured that the sample was chosen to be reasonably representative, as they would have 
put in numbers “provided by the Norwegian Bureau of Census” or the National Patient 
Register. The problem is, however, that the numbers gathered from these sources might 
differ by several 100 %, as illustrated in the text.  
 
Because of dissimilarities in methodology, perspective, definitions, evaluation principles 
and data sources used in different quality of life and cost of MS-studies, comparisons of 
findings from different studies may in general be of limited value. Still, we found the 
Swedish study by Henriksson et al.from 2001, to be of special interest for comparisons 
with our work because their study was for our closest neighboring country and also 
seemed to have been carried out in a way that corresponded well with the way we 
planned to arrive at our own best cost estimates for Norway. Also, the total cost per MS-
patient turned out to be reasonably similar in the two countries. A closer look beneath this 
surface, however, revealed dramatic differences in several instances. 
 
Relating the information on cost of MS and the patients´ experienced quality of life to 
illness severity adds still more uncertainty both because less information will be available 
for each individual level of severity, and because of additional methodological 
imperfections and difficulties.  
 
 
Conclusion 
 
The huge uncertainty found for almost all the results of our study, indicates that at least 
Norway, but  probably also other countries have a long way to go before studies like our 
in general might be regarded as providing acceptable information for decisions as 
important as those in the health sector. 
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